Drug Trial Radar · NCT02746796
Study of ONO-4538 in Gastric Cancer
Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
680
Planned (sponsor's estimate)
Start
Mar 2016
Primary completion
Jan 2020
Study completion Nov 17, 2022
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine + Oxaliplatin). In part 2, the investigator or the subinvestigator will choose a chemotherapy (SOX or CapeOX therapy), taking into account the condition of each subject. Part 2 is planned to evaluate the efficacy and safety of ONO-4538 + chemotherapy in comparison with placebo + chemotherapy.
Conditions
- Gastric Cancer
Interventions
ONO-4538Drug
OxaliplatinDrug
Tegafur- Gimeracil-Oteracil potassiumDrug
CapecitabineDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (central assessment by IRRC) (only Part 2)Time frame: Up to study completion (estimated time frame: 48 months)
- Overall survival (only Part 2)Time frame: Up to study completion (estimated time frame: 54 months)
Locations
130 sites in 3 countries. Site status is shown where the registry gives one.
Akita Clinical Site
Akita, Japan
Chiba Clinical Site1
Chiba, Japan
Chiba Clinical Site2
Chiba, Japan
Fukui Clinical Site
Fukui, Japan
Fukuoka Clinical Site1
Fukuoka, Japan
Fukuoka Clinical Site2
Fukuoka, Japan
Fukuoka Clinical Site3
Fukuoka, Japan
Fukuoka Clinical Site4
Fukuoka, Japan
Fukushima Clinical Site
Fukushima, Japan
Hiroshima Clinical Site1
Hiroshima, Japan
Hiroshima Clinical Site2
Hiroshima, Japan
Hiroshima Clinical Site3
Hiroshima, Japan
Kumamoto Clinical Site1
Kumamoto, Japan
Kumamoto Clinical Site2
Kumamoto, Japan
Kumamoto Clinical Site3
Kumamoto, Japan
Kyoto Clinical Site1
Kyoto, Japan
Kyoto Clinical Site2
Kyoto, Japan
Kyoto Clinical Site3
Kyoto, Japan
Niigata Clinical Site
Niigata, Japan
Okayama Clinical Site
Okayama, Japan
Osaka Clinical Site1
Osaka, Japan
Osaka Clinical Site2
Osaka, Japan
Osaka Clinical Site3
Osaka, Japan
Osaka Clinical Site4
Osaka, Japan
Shizuoka Clinical Site
Shizuoka, Japan
Tokushima Clinical Site
Tokushima, Japan
Toyama Clinical Site
Toyama, Japan
Wakayama Clinical Site
Wakayama, Japan
Yamagata Clinical Site
Yamagata, Japan
Aichi Clinical Site
Nagoya, Aichi-ken, Japan
Aomori Clinical Site
Hirosaki, Aomori, Japan
Aomori Clinical Site
Misawa, Aomori, Japan
Chiba Clinical Site
Funabashi, Chiba, Japan
Chiba Clinical Site
Kamogawa, Chiba, Japan
Chiba Clinical Site
Kashiwa, Chiba, Japan
Ehime Clinical Site1
Matsuyama, Ehime, Japan
Ehime Clinical Site2
Matsuyama, Ehime, Japan
Fukuoka Clinical Site
Iizuka, Fukuoka, Japan
Fukuoka Clinical Site1
Kitakyushu, Fukuoka, Japan
Fukuoka Clinical Site2
Kitakyushu, Fukuoka, Japan
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.